Third Novartis Phase III trial shows Kisqali® combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer

Third Novartis Phase III trial shows Kisqali® combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer

Jun 03, 2018
Source URL: https://qa1.novartis.us/us-en/news/media-releases/third-novartis-phase-iii-trial-shows-kisqali-combination-therapy-significantly-improves-pfs-hrher2-advanced-breast-cancer-0

List of links present in page
  1. https://qa1.novartis.us/us-en/us-en/news/media-releases/third-novartis-phase-iii-trial-shows-kisqali-combination-therapy-significantly-improves-pfs-hrher2-advanced-breast-cancer-0